Stevanato Group S.p.A.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products...
Latest News
6 days ago · seekingalpha.com
Conestoga Small Cap Composite Q3 2026 Portfolio ActivityThe Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.
6 days ago · businesswire.com
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System SelectionPIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie.
13 days ago · businesswire.com
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to di.
2 months ago · seekingalpha.com
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptStevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · businesswire.com
Stevanato Group to Participate in Two Upcoming Investor ConferencesPIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.
2 months ago · gurufocus.com
A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71On September 01, 2026, Stevanato Group SpA (STVN) shares fell 3.4% to a current price of $20.71, trading within a 52-week range of $12.89 to $28.00. This recent
2 months ago · gurufocus.com
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells InvestorsOn August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to
3 months ago · zacks.com
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 months ago · seekingalpha.com
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call TranscriptStevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
3 months ago · zacks.com
Stevanato Group (STVN) Q2 Earnings Top EstimatesStevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove STVN